Discover a parent's essential guide to navigating pediatric urology, focusing on minimal intervention and advanced medical ...

It is used both to treat tumours and to help clinicians determine whether they are cancerous, as well as their grade and ...

Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBCBCG-unresponsive patients achieved an 80% CR rate at 12 months and 94% CR rate at any time ...

Patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy proceed directly to radical cystectomy with pelvic lymph-node dissection. Perioperative therapy may ...

For most people with bladder cancer, the first red flag is literally red: blood in the urine. But for people with color blindness, that warning sign may be easy to miss — and missing it could prove ...

One of the more common complications is a ureteral obstruction, which is a blockage of the tubes that drain from the kidneys into the bladder. “The tumor can block the ability of urine to flow from ...

Myasthenia gravis (MG) or its treatments may lead to urinary symptoms. Studies suggest a link between overactive bladder symptoms and a common MG medication called pyridostigmine. Urinary symptoms in ...

TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, consistent release of chemotherapy proved far more effective than traditional ...

The FDA has approved Pfizer and Astellas’ Padcev (enfortumab vedotin-ejfv) plus Merck’s Keytruda (pembrolizumab) as a perioperative treatment for adults with muscle-invasive bladder cancer who are ...

Editor's Note: This is an excerpt from WBUR's weekly health newsletter, CommonHealth. If you like what you read and want it in your inbox, sign up here. Bladder cancer hits men especially hard. The ...

An experimental treatment method has shown promise in fighting a hard-to-treat form of bladder cancer known as BCG-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC). BCG (Bacillus ...

Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...